• New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccine
  • Poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting on Friday, November 10th

VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI) today announced that Catalina Soare, VBI’s head of preclinical development, will present new preclinical data demonstrating the potency of VBI-1901 as a therapeutic vaccine candidate against glioblastoma multiforme (GBM) at the 32nd annual meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland, on November 10, 2017.

Dr. Soare will present preclinical data, which confirms the use of intradermal delivery of VBI’s enveloped virus-like particle (eVLP), VBI-1901, may be a potent “off-the-shelf” dendritic cell vaccine. Following intradermal injection of VBI-1901, migratory dendritic cells at the injection site were confirmed to stimulate potent, adaptive T-cell immunity.

The FDA recently accepted VBI’s IND for VBI-1901. The company expects to initiate enrollment in a multi-center Phase 1/2a clinical study evaluating VBI-1901 in patients with recurrent GBM in the fourth quarter of 2017.

Event Details
  • Event: Annual Meeting of the Society for Immunotherapy of Cancer
  • Date: Friday, November 10, 2017
  • Time: 12:30 PM – 2:00 PM EST; 6:30 PM – 8:00 PM EST
  • Location: Gaylord National Hotel & Convention Center, National Harbor, Maryland
  • Event Website: http://www.sitcancer.org/education/annualmeeting
GBM Program Background

Glioblastoma is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and is exceptionally lethal, with median patient survival of less than 16 months.

Targeted immunotherapy may provide a promising adjunct or alternative to conventional GBM treatment. Immunotherapy is a fundamentally different way of treating cancer that stimulates the patient’s immune system to resume its attack on tumors. While conventional therapies are non-specific and may damage surrounding normal tissues, targeted immunotherapy may offer a highly specific and potentially long-lasting treatment approach that leverages the immune system to protect against cancer.

Developing a broadly applicable GBM immunotherapy requires the identification of antigens that are consistently expressed on GBM tumor cells. Recent research has demonstrated that an anti-CMV dendritic cell vaccination regimen may extend overall survival in patients with GBM. Thus, effective targeting of CMV antigens may represent an attractive strategy for a GBM immunotherapy.

To learn more about VBI’s GBM immunotherapy program, visit: https://www.vbivaccines.com/gbm/